300869.SZ
Contec Medical Systems Co. Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 11.23
−2.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 456.4M | 468.0M | 479.8M | 746.9M | 712.1M |
| Cost of Revenue | 244.7M | 243.1M | 243.0M | 316.8M | 374.0M |
| Gross Profit | 211.8M | 224.9M | 236.8M | 430.1M | 338.1M |
| Operating Expenses | |||||
| R&D Expense | 90.8M | 91.7M | 105.2M | 110.6M | 93.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 42.0M | 39.5M | 40.8M | 41.8M | 34.4M |
| Selling & Marketing Expense | 113.7M | 110.0M | 88.5M | 117.7M | 90.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 271.8M | 252.9M | 224.6M | 252.1M | 177.7M |
| Cost and Expenses | 516.5M | 496.0M | 467.7M | 568.9M | 551.7M |
| Operating Income (EBIT) | (52.4M) | (26.3M) | (67.6M) | 186.7M | 219.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (52.7M) | (26.9M) | (73.9M) | 186.1M | 219.4M |
| Income Tax Expense | (3.6M) | (2.5M) | 4.0M | 20.4M | 23.2M |
| Bottom Line | |||||
| Net Income | (49.1M) | (24.4M) | (77.9M) | 165.8M | 196.2M |
| Earnings from Cont. Ops | (49.1M) | (24.4M) | (77.9M) | 165.8M | 196.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (49.1M) | (24.4M) | (77.9M) | 165.8M | 196.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.12) | (CN¥0.06) | (CN¥0.19) | CN¥0.41 | CN¥0.49 |
| Diluted EPS | (CN¥0.12) | (CN¥0.06) | (CN¥0.17) | CN¥0.40 | CN¥0.48 |
| Revenue Per Share | CN¥1.14 | CN¥1.15 | CN¥1.17 | CN¥1.85 | CN¥1.78 |
| Shares | |||||
| Basic Shares Outstanding | 402.0M | 407.1M | 410.0M | 404.3M | 400.4M |
| Diluted Shares Outstanding | 402.0M | 407.1M | 410.0M | 404.3M | 400.4M |
| Profitability Metrics | |||||
| EBITDA | — | (590.3K) | (41.5M) | 212.3M | 238.2M |
| D&A | — | 25.7M | 26.0M | 25.5M | 19.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026